2025
Demographic, Socioeconomic, and Clinical Variables Associated With Nonmedical Pharmaceutical Opioid Use and Heroin Use Among US Adults in 2021 to 2022.
Moss M, Buonora M, Becker W. Demographic, Socioeconomic, and Clinical Variables Associated With Nonmedical Pharmaceutical Opioid Use and Heroin Use Among US Adults in 2021 to 2022. Substance Abuse 2025, 29767342251348150. PMID: 40667774, DOI: 10.1177/29767342251348150.Peer-Reviewed Original ResearchUS adultsOpioid useLower self-rated healthSelf-rated healthSevere mental illnessNational Survey on Drug Use and HealthDrug Use and HealthPublic health effortsHeroin useClinical variablesMultivariate logistic regression modelCross-sectional studyAssociated with opioid useLogistic regression modelsSedative/tranquilizer useOpioid overdose epidemicOpioid use patternsMental illnessHealth effortsMiddle age groupNonmedical opioid usePharmaceutical opioid useNonmedical stimulant useSocioeconomic variablesMultisubstance useIncorporating Patient and Provider Voices into the Veterans Pain Care Organizational Improvement Comparative Effectiveness Study: Informing Future Implementation
Hagedorn H, Purcell N, DeRonne B, Salameh H, Becker W, Seal K, Krebs E. Incorporating Patient and Provider Voices into the Veterans Pain Care Organizational Improvement Comparative Effectiveness Study: Informing Future Implementation. Journal Of General Internal Medicine 2025, 1-13. PMID: 40481383, DOI: 10.1007/s11606-025-09639-8.Peer-Reviewed Original ResearchInterdisciplinary pain teamVeterans Health AdministrationClinical championsProcess evaluationLeadership supportReducing opioid useConclusionThis process evaluationQualitative process evaluationPrimary care settingOpioid useComparative effectiveness studiesRE-AIMPatient involvementConstructs of implementationPain teamCare settingsPatient perspectiveCategorize themesIdentified themesImprove painClinical teamProvider voicesHealth AdministrationIncorporating patientEffectiveness trialLong-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study
Macmadu A, Li Y, Bhondoekhan F, Chang C, Bahji A, Crystal S, Gordon K, Kerns R, Vickers-Smith R, Edelman E, Marshall B. Long-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study. Addictive Behaviors Reports 2025, 22: 100619. PMID: 40547483, PMCID: PMC12182372, DOI: 10.1016/j.abrep.2025.100619.Peer-Reviewed Original ResearchDepressive symptom severityVeterans Aging Cohort StudySymptom severityOpioid useCohort studySubstance use disordersPrescription opioid useProspective cohort studyOpioid use disorderAging Cohort StudyMental health servicesDose-response patternGeneralized Estimating Equation modelsVeterans Health Administration sitesUse disorderClinical characteristicsProspective cohortBidirectional associationsFollow-upStudy entryOpioidHarm reduction servicesBidirectional relationshipPLHIVAdministration siteA Novel Electronic Health Record-Integrated Clinical Pathway for Nephrolithiasis: Development and Management Outcomes.
Lokeshwar S, Choksi A, Smani S, Heacock D, Kanaparthy N, Shaheen D, Dashevsky M, Martin T, Singh D, Motamedinia P, Sangal R. A Novel Electronic Health Record-Integrated Clinical Pathway for Nephrolithiasis: Development and Management Outcomes. Urology Practice 2025, 101097upj0000000000000847. PMID: 40459510, DOI: 10.1097/upj.0000000000000847.Peer-Reviewed Original ResearchEmergency departmentRenal colicClinical pathwayPain controlEvidence-based pain managementED patient careInadequate discharge planningAcute renal colicMedical expulsive therapyUrological follow-upMann-Whitney <i>Retrospective cohort studyEnhanced pain controlDischarge planningHealth systemDischarge practicesKetorolac doseOpioid alternativesPatient careExpulsive therapyLidocaine usePathway useOpioid useStandard carePain managementUnderstanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site “Subthreshold Opioid Use Disorder Prevention” (STOP) Trial
Rostam-Abadi Y, Liebschutz J, Subramaniam G, Stone R, Appleton N, Mazel S, Alexander K, Brill S, Case A, Gelberg L, Gordon A, Hong H, Incze M, Kawasaki S, Kim T, Kline M, Lovejoy T, McCormack J, Zhang S, McNeely J. Understanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site “Subthreshold Opioid Use Disorder Prevention” (STOP) Trial. Journal Of General Internal Medicine 2025, 1-10. PMID: 40457116, DOI: 10.1007/s11606-025-09613-4.Peer-Reviewed Original ResearchOpioid use disorderMental health symptomsHigh-risk useOpioid useHealth symptomsConsequences of opioid useSymptoms of opioid use disorderBaseline characteristics of participantsCollaborative care interventionRates of polysubstance usePrimary care patientsPrimary care sitesOpioid use disorder preventionPrimary care settingSelf-reported demographic characteristicsModerate-severe painSevere opioid use disorderCharacteristics of participantsModerate-severe anxietyPrimary careCare interventionsCare sitesCare settingsOpioid medicationsNon-HispanicTemporal Trends in Opioid Use and Associated Outcomes for Patients Living with Advanced Cancer
Jairam V, Lindsay M, Soulos P, Gross C, Prsic E, Baum L, Park H. Temporal Trends in Opioid Use and Associated Outcomes for Patients Living with Advanced Cancer. Journal Of Pain And Symptom Management 2025 PMID: 40403779, DOI: 10.1016/j.jpainsymman.2025.05.007.Peer-Reviewed Original ResearchPain-related ED visitsOpioid useGabapentinoid useOpioid-related encountersAdvanced cancerOpioid prescribingED visitsAdvanced solid tumor cancersEnd Results (SEER)-Medicare databaseHigh-risk opioid useNonopioid pain medicationsMultivariate logistic regression modelNon-cancer patientsSolid tumor cancersPain controlPain medicationInvestigate time trendsIndex dateLogistic regression modelsCancer cohortOpioidNoncancer patientsOpioid epidemicPatientsNoncancer cohortNon-fatal Overdose and Associated Factors Among People Who Use Opioids: Findings From a Cross-sectional Study
Sujan M, Wickersham J, Khati A, Paudel K, Gautam K, Liautaud D, Crim H, Thapa A, Copenhaver M, Shrestha R. Non-fatal Overdose and Associated Factors Among People Who Use Opioids: Findings From a Cross-sectional Study. Journal Of Community Health 2025, 1-10. PMID: 40381076, DOI: 10.1007/s10900-025-01480-8.Peer-Reviewed Original ResearchNon-fatal overdoseOpioid dependenceCross-sectional studySuicidal ideationHistory of opioid useOpioid overdoseAlcohol use disorderNon-fatal opioid overdoseMental health symptomsAge of participantsParticipants self-reportedHarm reduction interventionsSocio-demographic characteristicsOpioid useEffective prevention strategiesUse disorderDepressive symptomsTargeted harm reduction interventionsHealth symptomsMultivariate logistic regression analysisLogistic regression analysisReduction interventionsOlder participantsCross-sector collaborationRisk of overdoseOpioid Dose Variation in Cardiac Surgery: A Multicenter Study of Practice
Fisher C, Janda A, Zhao X, Deng Y, Bardia A, Yanez N, Burns M, Aziz M, Treggiari M, Mathis M, Lin H, Schonberger R. Opioid Dose Variation in Cardiac Surgery: A Multicenter Study of Practice. Anesthesia & Analgesia 2025, 140: 1016-1027. PMID: 39167548, PMCID: PMC11842693, DOI: 10.1213/ane.0000000000007128.Peer-Reviewed Original ResearchCardiac surgeryOpioid doseDose variationIntraoperative opioid administrationIntraoperative opioid doseHigh-dose opioidsAdult cardiac surgerySurgical differencesOpioid-freeOpioid administrationOpioid useMultimodal analgesiaAnalgesic techniquesCardiopulmonary bypassMulticenter studyFentanyl equivalentsSufentanil infusionSurgical patientsOpioidSurgeryAnesthetic techniqueCardiac casesAttending anesthesiologistPatientsDoseArginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial
Morris C, Hatabah D, Korman R, Gillespie S, Bakshi N, Brown L, Harris F, Leake D, Rees C, Khemani K, Vichinsky E, Locke A, Wynn B, Griffiths M, Wilkinson H, Kumari P, Sudmeier L, Shiva S, Dampier C. Arginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial. American Journal Of Hematology 2025, 100: 1119-1131. PMID: 40270092, PMCID: PMC12148696, DOI: 10.1002/ajh.27692.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialPatient-reported outcomesArginine therapyArginine bioavailabilityPain scoresVaso-occlusive pain episodesParenteral opioid useTertiary-care children's hospitalPlasma protein carbonyl levelsDose-dependent increasePost hoc sensitivity analysisOxidative stressSickle cell diseaseMeasures of oxidative stressDecreased oxidative stressOpioid-sparingStandard-dosePlacebo groupPlacebo-ControlledPatient 3Primary endpointLoading-doseOpioid usePain episodesClinical outcomesEpidemiology of Opioid Use, Misuse, and Overdoses
Draghmeh K, Gold M, Fuehrlein B. Epidemiology of Opioid Use, Misuse, and Overdoses. Current Addiction Reports 2025, 12: 36. DOI: 10.1007/s40429-025-00649-4.Peer-Reviewed Original ResearchOpioid use disorderEpidemiology of opioid useComplex public health challengesMental health disordersRisk factorsPublic health challengeOpioid useHarm reduction programsSocioeconomic disadvantagePsychosocial interventionsAccess barriersHealth disordersHealth challengesReduction programsOverdose deathsImprove outcomesGenetic predispositionCollaborative effortsPolysubstance useTreatment retentionEpidemiologyInnovative therapiesIncreasing overdose deathsReviewThis reviewLimited accessibilityBuprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids
Becker W, Seal K, Nelson D, DeRonne B, Kats A, Morasco B, Frank J, Makris U, Painter J, Allen K, Mixon A, Bohnert A, Reznik T, Hagedorn H, Hammett P, Borsari B, Baxley C, Krebs E. Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids. JAMA Internal Medicine 2025, 185: 372-381. PMID: 39960730, PMCID: PMC11833656, DOI: 10.1001/jamainternmed.2024.8361.Peer-Reviewed Original ResearchThis study assessed whether switching chronic pain patients from high-dose opioids to buprenorphine improved pain or reduced opioid use, finding no improvements compared with not offering the switch.Understanding the Pain Experience and Treatment Considerations Along the Spectrum of Peripheral Artery Disease: A Scientific Statement From the American Heart Association
Smolderen K, Ujueta F, Behan D, Vlaeyen J, Jackson E, Peters M, Whipple M, Phillips K, Chung J, Mena-Hurtado C, Research O. Understanding the Pain Experience and Treatment Considerations Along the Spectrum of Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation Cardiovascular Quality And Outcomes 2025, 18: e000135. PMID: 39925269, DOI: 10.1161/hcq.0000000000000135.Peer-Reviewed Original ResearchConceptsPeripheral arterial diseaseArtery diseaseMultimodal pain management strategiesPain experienceAtypical leg painChronic pain syndromesGeneration of painMultimodal pain managementChronic pain experiencePain management strategiesIschemic rest painPhantom limb painAmerican Heart AssociationNeuropathic painLeg painNeuropathic mechanismsPain syndromeOpioid useChronic painRest painPain managementHeart AssociationLimb painClinical subgroupsIntermittent claudicationT122 Developing e-Covery: A Geographic Ecological Momentary Intervention to Support Recovery Among Individuals Reporting Co-Occurring Alcohol and Opioid Use
Viera A, Edelman E, Muilenberg J, Lauckner C, Kershaw T. T122 Developing e-Covery: A Geographic Ecological Momentary Intervention to Support Recovery Among Individuals Reporting Co-Occurring Alcohol and Opioid Use. Drug And Alcohol Dependence 2025, 267: 111890. DOI: 10.1016/j.drugalcdep.2024.111890.Peer-Reviewed Original ResearchBuprenorphine induces human fetal membrane sterile inflammation
Lynn T, Kelleher M, Georges H, McCauley E, Logan R, Yonkers K, Abrahams V. Buprenorphine induces human fetal membrane sterile inflammation. Journal Of Reproductive Immunology 2025, 168: 104445. PMID: 39914058, PMCID: PMC11890952, DOI: 10.1016/j.jri.2025.104445.Peer-Reviewed Original ResearchConceptsOpioid-use disorderPreterm birthToll-like receptor 4Prostaglandin E2Sterile inflammationRate of preterm birthAssociated with pregnancy complicationsInnate immune toll-like receptor 4Maternal-fetal interfaceNeutrophil chemokine IL-8Induce sterile inflammationM-opioid receptorCytokines IL-1bInflammatory cytokines IL-6Chemokine IL-8Cytokines IL-6Maternal morbidityPregnancy complicationsOpioid useOpioid-usersHuman FMInflammatory profileMembrane weakeningIL-1BPretermA deep learning analysis for dual healthcare system users and risk of opioid use disorder
Yin Y, Workman E, Ma P, Cheng Y, Shao Y, Goulet J, Sandbrink F, Brandt C, Spevak C, Kean J, Becker W, Libin A, Shara N, Sheriff H, Butler J, Agrawal R, Kupersmith J, Zeng-Trietler Q. A deep learning analysis for dual healthcare system users and risk of opioid use disorder. Scientific Reports 2025, 15: 3648. PMID: 39881142, PMCID: PMC11779826, DOI: 10.1038/s41598-024-77602-4.Peer-Reviewed Original ResearchConceptsRisk of opioid use disorderOpioid use disorderDeep neural networksUse disorderClinical factorsIncreased risk of opioid use disorderOpioid use disorder riskOpioid prescribing guidelinesNatural language processing of clinical notesDeep neural network modelU.S. veteransSubstance useOpioid useNatural language processingRetrospective studyBaltimore VA Medical CenterVA Medical CenterIncreased riskPrescribing guidelinesDrug useRisk factorsOpioidMedical CenterVeteransVeterans Health AdministrationHarm Reduction Strategies for Opioid Use Disorder
Knio L, Capurso N. Harm Reduction Strategies for Opioid Use Disorder. Current Addiction Reports 2025, 12: 1. DOI: 10.1007/s40429-025-00630-1.Peer-Reviewed Original ResearchOpioid use disorderHarm reduction strategiesImprove health outcomesEvidence-based interventionsHarms associated with opioid useEvidence-based implementationSyringe service programsUse disorderSupervised consumption sitesReduction strategiesReduce stigmaHealth outcomesNaloxone distributionRelated harmPolicy reformsSocial barriersService programsSocial justiceMarginalized populationsFentanyl contaminationOpioid useDrug supplyHarmConsumption sitesInterventionComments on: Bariatric surgery targeting opioid prescribing: a national model for effectively reducing opioid use after bariatric surgery
Ying L, Ghiassi S. Comments on: Bariatric surgery targeting opioid prescribing: a national model for effectively reducing opioid use after bariatric surgery. Surgery For Obesity And Related Diseases 2025, 21: 410-411. PMID: 39864987, DOI: 10.1016/j.soard.2024.12.021.Peer-Reviewed Original ResearchThe relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: Does it depend on prior history of cannabis use?
Martins S, Bruzelius E, Mauro C, Santaella-Tenorio J, Boustead A, Wheeler-Martin K, Samples H, Hasin D, Fink D, Rudolph K, Crystal S, Davis C, Cerdá M. The relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: Does it depend on prior history of cannabis use? International Journal Of Drug Policy 2025, 136: 104687. PMID: 39793270, PMCID: PMC11821435, DOI: 10.1016/j.drugpo.2024.104687.Peer-Reviewed Original ResearchConceptsCannabis lawsCannabis useNational Survey on Drug Use and Health (NSDUHDrug Use and Health (NSDUHRecreational cannabis lawsState fixed effectsAvailability of cannabisOpioid outcomesOpioid useAssociated with changesHistory of cannabis useLawOpioid misusePast-year cannabis useLifetime cannabis useState policySensitivity to unmeasured confoundingMisuseIndividual level covariatesCannabisLogistic regression modelsAssociated with reductionsOpioidCollider biasFalse discovery rateFrom Chronic Opioids for Pain to Microgram Buprenorphine: Key Factors in an Increasingly Recommended Transition.
Hickey T, Hitt J. From Chronic Opioids for Pain to Microgram Buprenorphine: Key Factors in an Increasingly Recommended Transition. Pain Physician Journal 2025, 28: 59-67. PMID: 39903018.Peer-Reviewed Original ResearchConceptsOpioid therapyBuprenorphine exposureTotal dose of opioidsVeterans Health AdministrationChronic opioid therapyDoses of opioidsChronic pain managementOutpatient opioid prescriptionsReducing opioid useFull-agonist opioidsPrescription of buprenorphineTransition to buprenorphineAssociated with lower oddsVeterans Affairs Corporate Data WarehouseBaseline opioidChronic opioidsOpioid doseAgonist opioidsOpioid exposureHealth AdministrationOpioid prescriptionsOpioid useSurrogate markerLarge-scale observational studiesBuprenorphine initiation
2024
A Prehospital Quality Improvement Framework to Reduce Mortality and Other Harms Associated with Opioid Use Disorder
Glenn M, Crowe R, Dorsett M, Taigman M, Herring A, Mercer M, Joiner A, Venkatesh A, Davis C, Hawk K, Hern H, Carroll G, Cabañas J, D’Onofrio G, Samuels E. A Prehospital Quality Improvement Framework to Reduce Mortality and Other Harms Associated with Opioid Use Disorder. Prehospital Emergency Care 2024, 29: 510-518. PMID: 39671519, DOI: 10.1080/10903127.2024.2428671.Peer-Reviewed Original ResearchEmergency medical servicesOpioid use disorderQI frameworkQuality improvementHarm reductionQuality improvement frameworkHarms associated with opioid useEvidence-based practiceReduce mortalityReduce overdose deathsEscalating overdose crisisImproved frameworkMedical servicesMultidisciplinary teamOverdose crisisAddiction medicinePublic healthOverdose deathsSubject matter expertsPrehospitalOpioid useQuality measuresAdverse outcomesUse disorderHarm
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply